TABLE 2.
Participant characteristics, symptoms during acute infection, and time since molecular confirmed positive COVID-19 test for COVID-19 groups after stratification by mMRC dyspnea grade (0 = normal, ≥1 = dyspneic) and Controls. BMI, body mass index; BSA, body surface area; PCFS, Post-COVID Functional Scale; EQ-5D VAS, EuroQol 5-Dimension visual analog scale.
| COVID split by mMRC | mMRC≥1 | mMRC = 0 | Control | |
|---|---|---|---|---|
| Sex (F/M), N | 13/3 | 13/3 | 13/3 | |
| Age (years) | 39 (11) | 39 (11) | 41 (11) | |
| Height (cm) | 166 (6) | 170 (9) | 167 (6) | |
| BMI (kg/m2) | 25.0 (3.2) | 23.7 (3.3) | 23.6 (3.3) | |
| BSA (m2) | 1.78 (0.16) | 1.79 (0.21) | 1.75 (0.15) | |
| Smoking History (n, %) | 3 (23) | 2 (12) | 3 (23) | |
| Acute COVID | Symptom Length (days) | 23 (22) | 17 (15) | - |
| Hospitalization (n, %) | 4 (24%) | 2 (12%) | - | |
| Emergency Visit (n, %) | 4 (24%) | 2 (12%) | - | |
| Dyspnea (n, %) | 16 (94%) | 9 (53%) | - | |
| Fatigue (n, %) | 13 (76%) | 15 (88%) | - | |
| Fever (n, %) | 12 (71%) | 12 (71%) | - | |
| Anosmia (n, %) | 12 (71%) | 10 (59%) | - | |
| Ageusia (n, %) | 12 (71%) | 10 (59%) | - | |
| Muscle Pain (n, %) | 11 (65%) | 8 (47%) | - | |
| Headaches (n, %) | 12 (71%) | 10 (59%) | - | |
| Cough (n, %) | 13 (76%) | 8 (47%) | - | |
| Diarrhea (n, %) | 4 (24%) | 1 (6%) | - | |
| Time post infection | Days post positive test | 202 (74) | 215 (104) | - |
| Quality of Life | PCFS | 2 (1)†‡ | 0 (0) | 0 (0) |
| EQ-5D VAS | 66 (19)†‡ | 83 (9) | 89 (9) | |
†: p < 0.05 vs. Con; ‡: p < 0.05 vs. mMRC = 0.